Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Антисмысловые олигонуклеотиды: перспективное направление в открытии и разработке лекарственных средств
2020-06-26
SCID: 54.1/rexgxfu6
Discuss with AI
RNA-targeted therapeuticsantisense oligonucleotideschemical modificationsmicroRNA therapeuticsoligonucleotide delivery
Figures from the paper
Abstract (AI)
Antisense oligonucleotides (ASOs) bind sequence specifically to the target RNA and modulate protein expression through several different mechanisms. The ASO field is an emerging area of drug development that targets the disease source at the RNA level and offers a promising alternative to therapies targeting downstream processes. To translate ASO-based therapies into a clinical success, it is crucial to overcome the challenges associated with off-target side effects and insufficient biological activity. In this regard, several chemical modifications and diverse delivery strategies have been explored. In this review, we systematically discuss the chemical modifications, mechanism of action, and optimized delivery strategies of several different classes of ASOs. Further, we highlight the recent advances made in development of ASO-based drugs with a focus on drugs that are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for clinical applications. We also discuss various promising ASO-based drug candidates in the clinical trials, and the outstanding opportunity of emerging microRNA as a viable therapeutic target for future ASO-based therapies.
Key Findings
1
ASO therapies act at the disease-source RNA level, offering an alternative to treatments targeting downstream biological processes.
2
Antisense oligonucleotides bind target RNA sequence-specifically and modulate protein expression through multiple mechanisms.
3
Chemical modifications and optimized delivery strategies are being developed to improve ASO activity, specificity, and therapeutic performance.
4
FDA- and EMA-approved ASO drugs, clinical-stage candidates, and emerging microRNA targets demonstrate expanding therapeutic opportunities for ASO-based treatments.
5
Off-target side effects and insufficient biological activity remain major barriers to translating ASO therapies into clinical success.
Research Object
Antisense oligonucleotide-based therapies and drugs
Research Subject
Chemical modifications, mechanisms of action, delivery strategies, therapeutic development, and clinical advancement of antisense oligonucleotides
Publication Details
Publication Date
2020-06-26
Journal
Journal of Clinical Medicine
Publisher
Multidisciplinary Digital Publishing Institute
ISSN
2077-0383
Cited by
622
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest